Expert Interview
A Second View: Examining Biocryst's BCX9930 (oral Factor D inhibitor) for the treatment in patients with C3 Glomerulopathy
Ticker(s): BCRXInstitution: Mass General | Harvard
- Clinical researcher & clinician in academic nephrology practice; Nephrologist at Massachusetts General Hospital and Instructor in Medicine at Harvard Medical School.
- Currently manages 8-10 patients with CKD associated pruritus, and 6 patients with C3 glomerulopathy.
- Conducts patient-oriented research in the areas of calciphylaxis, vascular calcification and hyponatremia, has authored over 50 peer-reviewed research articles, and research is funded by organizations including the American Kidney Fund & the National Kidney Foundation.
Roughly how many patients with C3G do you currently manage?
Added By: dami_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for BCX9930?
Added By: dami_adminWhat benefit, if any would BCX9930 provide over current therapies?
Added By: dami_adminWith Phase 1 and 2 being 'in vitro' at what point are patients going to test the benefits of this molucule?
Added By: dami_adminWhat is your view on C3 inhibition as a primary treatment option for IgAN vs. other development stage therapies that target APRIL and BAFF inhibition?
Added By: dami_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
